Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: Long-term follow-up and results

Teruo Ino, Hiroshi Kojima, Hitoshi Miyazaki, Fumio Maruyama, Ryo Sobue, Masataka Okamoto, Toshikazu Matsui, Kazuyuki Shimizu, Kohji Ezaki, Masami Hirano

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We designed a post-induction therapy including intensive sequential therapy with non-cross-resistant drugs in an effort to prolong disease-free survival (DFS) for adults with acute myelogenous leukemia. Forty-five patients entered this study and 33 of 35 patients entering complete remission received the post-induction therapy. With a median follow-up for survivors of 3.5 years from complete remission, the actuarial 5-year DFS was 46% ± 19% (95% confidence interval). The five-year DFS for patients over 45 years of age was comparable to that for patients under 45 years of age (50% ± 26% vs 47% ± 28%). Furthermore, the actuarial 5-year DFS for patients who required two courses of induction therapy was comparable to that for patients who required only one course of induction therapy (45% ± 29% vs 50% ± 25%). The toxicity of post-induction therapy was tolerable and no patients died during complete remission.

Original languageEnglish
Pages (from-to)577-584
Number of pages8
JournalLeukemia Research
Volume16
Issue number6-7
DOIs
Publication statusPublished - 1992

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: Long-term follow-up and results'. Together they form a unique fingerprint.

Cite this